// App-Quantinova.ai

: Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Relapsed/Refractory Non-Hodgkin Lymphoma Shows Activity in T-Cell Lymphoma

Researchers

Presenter

  • Graham P. Collins

Principal Investigators

  • Steven M. Horwitz

  • Andrew Davies

  • Anand Karnad

  • Felipe Samaniego

  • Alexander I Spira

  • Paul A Fields

  • Tobias Menne

  • Joseph Boni

  • Hans Cruz

  • Jay Feingold

  • Shui He

  • Jens Wuerthner

  • Mehdi Hamadani

Medical Centers

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY

  • Department of Psychology, University Southampton, Southampton, United Kingdom

  • Division of Hematology-Oncology, UT Health Cancer Center, San Antonio, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Virginia Cancer Specialists Research Institute, Fairfax, VA

  • Department of Medical Oncology, Guys and St Thomas NHS Foundation Trust, London, United Kingdom

  • Newcastle upon Tyne Hospitals Trust, Newcastle upon Tyne, United Kingdom

  • ADC Therapeutics America, Inc, Murray Hill

  • ADC Therapeutics, Switzerland, N/A, Switzerland

  • ADC Therapeutics America, Inc, Murray Hill

  • Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

Locations

  • United Kingdom

  • United States

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Non-Hodgkin's Lymphoma

  • T-cell lymphoma

  • Non‐Hodgkin Lymphoma

  • Lymphomas

  • Cutaneous T-cell lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • ADCT301

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Open Label

  • Multicenteric

  • Dose Escalation

Phase

  • I

Study Id's

  • N/A

Sponsors

  • ADC Therapeutics

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved